WESTBOROUGH, Mass. June 30 /PRNewswire/ -- Joseph B. Bolen, Ph.D., CSO of Millennium Pharmaceuticals, will chair the Focus on Cancer track IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics Conference and Exhibition taking place August 4-7 at the World Trade Center Boston & Seaport Hotel in Boston, MA. The cancer track presentations will focus on therapies for Hematology, Lung Cancer, Blood Borne Cancers, and Clinical Biomarkers.
Bolen has confirmed academia speakers including: Kenneth C. Anderson, M.D., Dana Farber Cancer Institute, Harvard Medical School; Bruce E. Johnson, M.D., Dana-Farber Cancer Institute, Harvard Medical School, Brigham and Women's Hospital; Mark A. Israel, M.D., Dartmouth Medical School; Neal Rosen, M.D., Ph.D., Memorial Sloan-Kettering Cancer Center; Massimo Loda, M.D., Dana Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School
Companies also giving technical conference presentations in this cancer track include Alnylam Pharmaceuticals, Amgen, Inc., ARIAD Pharmaceuticals Inc., ArQule, Inc., AstraZeneca R&D Boston, Bristol-Myers Squibb Company, Exelixis Inc, Genzyme Corporation, Infinity Pharmaceuticals, Inc, Merck Research Laboratories, Novartis Institutes for BioMedical Research, OncoMed Pharmaceuticals Inc, The Johnson & Johnson Family of Companies.
Additional conference sessions at Drug Discovery & Development of
Innovative Therapeutics conference include:
-- Cardio-Metabolic Disease Drug Discovery and Development
-- Translational Medicine/Research
-- Transforming Technologies
-- Anti-Infective Drug Discovery and Development
-- Neurodegenerative Disease Drug Discovery and Development
-- Inflammation in Drug Discovery and Development
-- Orphan Diseases: Fast-Tracking Orphan Drugs and Scientific Advances -- The Next Generation of Therapeutics: Emerging Biologics, Stem Cells and RNAi
IBC's Drug Discovery & Devel
|SOURCE IBC Life Sciences|
Copyright©2008 PR Newswire.
All rights reserved